Abbott Laboratories faces a criminal investigation by the Justice Department, after its recall of formulas due to complaints of bacterial infections exacerbated a shortage that began due to pandemic-induced supply chain issues.
The Justice Department was investigating conduct at Abbott’s plant in Sturgis, Michigan,
According to an Abbott spokesman, they are fully cooperating with the Justice Department without specifying what aspect of the company is under scrutiny.
In February 2022, Abbott, the biggest US supplier of baby formula, recalled Similac and other infant formula products produced at its Michigan facility after reports of bacterial infections in babies who had consumed products made there.
The US Food and Drug Administration found "shocking" results during an inspection, such as cracks in vital equipment, inadequate hand-washing, and evidence of previous bacterial contamination.
The plant has since reopened.


DOJ Ends Probe Into Fed Chair Jerome Powell, Boosting Kevin Warsh Confirmation Prospects
Oil Prices Slip as Strait of Hormuz Disruptions and U.S. Inventory Data Keep Markets on Edge
RFK Jr. Expands CDC Vaccine Advisory Panel's Scope Amid Legal Battles
SoftBank Shares Slide Despite Record Q4 Profit Fueled by OpenAI Investment
Why the future of marijuana legalization remains hazy despite high public support
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case
AcadeMedia Q3 Profit Climbs as International and Adult Education Segments Drive Growth
US Auto Industry Urges Trump to Block Chinese EV Market Access
Elon Musk’s China Influence Faces New Challenges Amid Rising EV Competition
Trump Reportedly Approves Plan to Remove FDA Commissioner Marty Makary Amid Growing Controversies
Nike Tariff Refund Lawsuit Sparks Consumer Backlash Over Price Increases
Nvidia CEO Jensen Huang to Join Trump’s China Visit Amid AI Chip Tensions
GOP Lawmakers Probe Sam Altman and OpenAI Ahead of Potential IPO
Oil Prices Hold Above $100 as Trump-Xi Meeting and Iran Conflict Keep Markets on Edge
Medicare to Cover GLP-1 Weight-Loss and Diabetes Drugs Starting July 1 



